Explore
Featured
Recent
Articles
Topics
Login
Upload
Featured
Recent
Articles
Topics
Login
Upload
Search Results for 'Tdf Ftc'
Tdf Ftc published presentations and documents on DocSlides.
EFFECTS ON RENAL FUNCTION OF A SWITCH FROM TENOFOVIR (TDF)
by tawny-fly
M Harris, . S Guillemi. , K Chan, B Yip. ,. . M ...
Switch from TDF to TAF
by easyho
GS-US-292-0109 Study. GS-US-311-1089 Study. . De...
Switch to DOR-TDF-3TC vs. Continued Baseline Regimen
by dorothy
DRIVE SHIFT. Switch to Doravirine-TDF-3TC versus C...
Switch
by lindy-dunigan
from. TDF to TAF. GS-US-292-0109 Study. GS-US-31...
1 Adam O’Neill Leonid
by celsa-spraggs
Reyzin. Boston University. . A Unified Approach ...
Comparison of NRTI combinations
by tawny-fly
ZDV/3TC . vs. TDF + FTC. Study 934. ABC/3TC . vs...
HBV resistance and
by calandra-battersby
immune escape . mutants. Anders Boyd, MPH, . PhD....
Switch to DRV/r + RAL
by debby-jeon
SPARE . Study. SPARE Study: switch to DRV/r + RAL...
ID Week Review 2015
by briana-ranney
Brian R. Wood, MD. Assistant Professor of Medicin...
Tyre Stewardship in Canada
by sherrill-nordquist
Presented to . New Zealand . Tyre. Industry Summ...
Comparative effectiveness of first-line antiretroviral therapy regimens: results from a large real-
by min-jolicoeur
implementation of Dolutegravir. Meireles MV. , Pa...
ACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals
by phoebe-click
ACTIVITY CODE . TD342. Antiretroviral Medications...
Common Pharmacomistakes in Advanced Illness
by tawny-fly
Common Pharmacomistakes in Advanced Illness Opioi...
Use of HCV DAAs with HIV Regimens
by robaut
Sam Lam, . PharmD. Annie Vong, . PharmD. 2/3/2017....
Evolving Options for HBV Therapy:
by desiron
Navigating the New Treatment Landscape. Outline. I...
Phase 2 of new ARVs Fostemsavir
by sportyinds
, . prodrug. of . temsavir. . (. attachment inhi...
WHO ARV Forecasting Meeting
by sistertive
Geneva, March 19 - 20 , 2015 1 | Treatment and C...
Target Date Funds and P
by unita
lan . S. ponsor Responsibilities. Marcia S. Wagner...
Brad Hare Nothing to Disclose
by beatrice
Kaiser Permanente San Francisco Medical Center. Sa...
Renal and Bone Safety of
by ashley
Tenofovir. . Alafenamide. . vs. . Tenofovir. ....
Total Soluble and Insoluble Dietary Fibre Contents of Wild Growing E
by alyssa
302 Vol. 32, 2014, No. 3: 302307Czech J. Fo...
Retirement Plan Consulting
by oconnor
Overview of Services. Table of Contents. About RPA...
Subjects with Renal Impairment Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Have Improved Renal and Bone Safety through 48 Weeks Study GS-US-292-0112
by micah
Tenofovir. . Disoproxil. . Fumarate. to . Tenof...
Raltegravir plus Ritonavir-Boosted Darunavir NEAT001/ANRS 143 Trial
by matthew167
NEAT001/ANRS 143 Trial. Darunavir/r + Raltegravir ...
Comparison of INSTI vs PI
by conchita-marotz
FLAMINGO. GS-236-0103. ACTG . A5257. WAVES. . De...
Update on risk factors, detection, and management of neuroc
by natalia-silvester
Scott Letendre, M.D.. Professor of . Medicine and...
CDC’s Interim Guidance on the Use of PrEP in Heterosexual
by calandra-battersby
Adults:. . Implications . for Clinical Practice....
COMING SOON:
by luanne-stotts
GENERIC ARVs. Tim Horn. Treatment Action Group. t...
TDF Microsoft Lync - Novembre 2010
by faustina-dinatale
Solutions & Architectures UC . Polycom. - Mi...
Highlights of AIDS
by calandra-battersby
2016: Advances in . HIV Prevention, Care and Trea...
COMPARATIVE INVESTIGATIONS ON NUTRITIONAL COMPOSITIONS OF O
by lois-ondreau
GROWN CEREALS AND THEIR RELATIONSHIPS. Dr. . Mirj...
Switch to PI/r + 3TC
by lois-ondreau
vs. PI/r . monotherapy. Study PIVOT. Study MOBID...
A Demonstration Open Label
by jane-oiler
Study to Assess the . Acceptability. , Safety. a...
ART Resistance and Second Line Regimens
by calandra-battersby
Learning Objectives. Understand when to switch to...
Roy M. Gulick, MD, MPH Gladys and Roland Harriman Professor of Medicine
by luanne-stotts
Chief, Division of Infectious Diseases. Weill Med...
ART in Resource-limited settings :
by liane-varnes
Progress and Challenges. Dr. B. B. . Rewari. MD,...
Generic treatments for HIV, HBV, HCV, TB could be mass produced for <$90 per patient
by min-jolicoeur
Dr Dzintars Gotham MBBS BSc(Hons). on behalf of. ...
Issues Affecting ART Success: Adherence, ARV Toxicity, Drug Interactions
by pamella-moone
Guidelines for the Use of Antiretroviral Agents i...
Duke Energy Carolinas ATC Calculation Process
by stefany-barnette
ATC Training. December 15. th. , 2011. Agenda. Ob...
Tenofovir nephrotoxicity in resource limited setting of Western India : Higher rate of renal functi
by conchita-marotz
A.Dravid. 1. ,A.Sadre. 2. ,S.Dhande. 1. , A.Borka...
Load More...